Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0DXDHU
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
huAb13v1-WD E2
|
|||||
| Synonyms |
huAb13v1 WD E2; huAb13v1WD E2
Click to Show/Hide
|
|||||
| Organization |
AbbVie, Inc.
|
|||||
| Drug Status |
Investigative
|
|||||
| Indication |
In total 1 Indication(s)
Small cell lung cancer [ICD11:2C25]
Investigative
|
|||||
| Drug-to-Antibody Ratio |
2
|
|||||
| Structure |
|
|||||
| Antibody Name |
huAb13v1
|
Antibody Info | ||||
| Antigen Name |
CD276 antigen (CD276)
|
Antigen Info | ||||
| Payload Name |
Undisclosed
|
|||||
| Linker Name |
huAb13v1-WD E2 linker
|
|||||
| Combination Type |
AbbVie's WD
|
|||||
General Information of The Activity Data Related to This ADC
Discovered Using Cell Line-derived Xenograft Model
Revealed Based on the Cell Line Data
| Standard Type | Value | Units | Cell Line | Disease Model |
|---|---|---|---|---|
| Half Maximal Effective Concentration (EC50) |
2
|
nM
|
NCI-H146 cells
|
Small cell carcinoma
|
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | 46.00% | Positive CD276 expression (CD276 +++/++) | ||
| Method Description |
Humanized anti-B7-H3 antibodies huAb13v1 was selected to beconjugated with several Bcl-xL inhibitor payloads and were evaluated in xenograft models of small cell lung cancer (H1650). The dose was 1 mg/kg/IP/QDx1.
|
||||
| In Vivo Model | H1650 CDX model | ||||
| In Vitro Model | Lung adenocarcinoma | NCI-H1650 cells | CVCL_1483 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | 48.00% | Positive CD276 expression (CD276 +++/++) | ||
| Method Description |
Humanized anti-B7-H3 antibodies huAb13v1 was selected to beconjugated with several Bcl-xL inhibitor payloads and were evaluated in xenograft models of small cell lung cancer (H1650). The dose was 3 mg/kg/IP/QDx1.
|
||||
| In Vivo Model | H1650 CDX model | ||||
| In Vitro Model | Lung adenocarcinoma | NCI-H1650 cells | CVCL_1483 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | 56.00% | Positive CD276 expression (CD276 +++/++) | ||
| Method Description |
The anti-tumor activity of huAb13vl as CZ or TX conjugates as purified DAR2 (E2)conjugates were characterized in enograft models of non-small cell lung cancer of human origin. The dose was ADC 3 mg/kg (Q14Dx3/IP).
|
||||
| In Vivo Model | NCI-H1650 CDX model | ||||
| In Vitro Model | Lung adenocarcinoma | NCI-H1650 cells | CVCL_1483 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | 60.00% | Positive CD276 expression (CD276 +++/++) | ||
| Method Description |
The anti-tumor activity of huAb13vl as CZ or TX conjugates as purified DAR2 (E2)conjugates were characterized in enograft models of non-small cell lung cancer of human origin. The dose was ADC 1 mg/kg (Q14Dx3/IP).
|
||||
| In Vivo Model | NCI-H1650 CDX model | ||||
| In Vitro Model | Lung adenocarcinoma | NCI-H1650 cells | CVCL_1483 | ||
| Experiment 5 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | 62.00% | Positive CD276 expression (CD276 +++/++) | ||
| Method Description |
Humanized anti-B7-H3 antibodies huAb13v1 was selected to beconjugated with several Bcl-xL inhibitor payloads and were evaluated in xenograft models of small cell lung cancer (H1650). The dose was 10 mg/kg/IP/QDx1.
|
||||
| In Vivo Model | H1650 CDX model | ||||
| In Vitro Model | Lung adenocarcinoma | NCI-H1650 cells | CVCL_1483 | ||
| Experiment 6 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | 67.00% | Positive CD276 expression (CD276 +++/++) | ||
| Method Description |
The anti-tumor activity of huAb13vl as CZ or TX conjugates as purified DAR2 (E2)conjugates were characterized in enograft models of non-small cell lung cancer of human origin. The dose was ADC 10 mg/kg (Q14Dx3/IP).
|
||||
| In Vivo Model | NCI-H1650 CDX model | ||||
| In Vitro Model | Lung adenocarcinoma | NCI-H1650 cells | CVCL_1483 | ||
| Experiment 7 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | 88.00% | Positive CD276 expression (CD276 +++/++) | ||
| Method Description |
The anti-tumor activity of huAb13vl as CZ or TX conjugates as purified DAR2 (E2)conjugates were characterized in enograft models of non-small cell lung cancer of human origin. The dose was ADC 1 mg/kg (Q4Dx6/IP) plus Docetaxel 7.5 mg/kg (Q14Dx3/IV).
|
||||
| In Vivo Model | NCI-H1650 CDX model | ||||
| In Vitro Model | Lung adenocarcinoma | NCI-H1650 cells | CVCL_1483 | ||
| Experiment 8 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | 98.00% | Positive CD276 expression (CD276 +++/++) | ||
| Method Description |
The anti-tumor activity of huAb13vl as CZ or TX conjugates as purified DAR2 (E2)conjugates were characterized in enograft models of non-small cell lung cancer of human origin. The dose was ADC 10 mg/kg (Q4Dx6/IP) plus Docetaxel 7.5 mg/kg (Q14Dx3/IV).
|
||||
| In Vivo Model | NCI-H1650 CDX model | ||||
| In Vitro Model | Lung adenocarcinoma | NCI-H1650 cells | CVCL_1483 | ||
| Experiment 9 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | 99.00% | Positive CD276 expression (CD276 +++/++) | ||
| Method Description |
The anti-tumor activity of huAb13vl as CZ or TX conjugates as purified DAR2 (E2)conjugates were characterized in enograft models of non-small cell lung cancer of human origin. The dose was ADC 3 mg/kg (Q4Dx6/IP) plus Docetaxel 7.5 mg/kg (Q14Dx3/IV).
|
||||
| In Vivo Model | NCI-H1650 CDX model | ||||
| In Vitro Model | Lung adenocarcinoma | NCI-H1650 cells | CVCL_1483 | ||
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) | 2.00 nM | Positive CD276 expression (CD276 +++/++) | ||
| Method Description |
The anti-tumor activity of these ADCs was tested in cytotoxicity assaysusing the H146 small cell lung cancer cell line. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
|
||||
| In Vitro Model | Small cell carcinoma | NCI-H146 cells | CVCL_1473 | ||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.